United States Castration Resistant Prostate Cancer Treatment Market 2025 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

The Global Castration Resistant Prostate Cancer Treatment Market is expected to grow at a CAGR of 9% during the forecasting period (2024-2031).

Key Development:

United States: Recent Industry Developments

✅ In August 2025, the FDA approved the initiation of a Phase 1 trial for KTX-2001, an NSD2 inhibitor, in combination with darolutamide for metastatic castration-resistant prostate cancer patients who have progressed after prior androgen receptor pathway inhibitor treatment.

✅ In August 2025, Vir Biotechnology announced the first patient dosed in Part 3 of its Phase 1 trial of VIR-5500, a PSMA-targeting T-cell engager, in combination with androgen receptor pathway inhibitors for metastatic prostate cancer.

✅ In August 2025, the FDA granted Fast Track designation to HLD-0915, a bifunctional small molecule therapy for metastatic castration-resistant prostate cancer, to expedite its development and review processes.

Japan: Recent Industry Developments

✅ In August 2025, a collaborative study in Japan introduced a multimodal MRI-ultrasound AI system for prostate cancer detection, outperforming traditional methods and radiologists in identifying clinically significant prostate cancer lesions.

✅ In August 2025, researchers in Japan developed Cryo-RL, an AI-driven reinforcement learning framework for automating prostate cancer cryoablation planning, enhancing treatment precision and efficiency.

✅ In August 2025, INmune Bio commenced an open-label Phase I/II trial of INKmuneTM in metastatic castration-resistant prostate cancer patients in Japan to evaluate its safety and efficacy.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/castration-resistant-prostate-cancer-treatment-market?sb

Castration-resistant prostate cancer (CRPC) treatments target prostate cancer that continues to progress despite androgen deprivation therapy. Therapies include novel hormonal agents, chemotherapy, immunotherapy, and radioligand therapy, aiming to slow disease progression, manage symptoms, and improve patient survival and quality of life.

Recent Mergers and acquisitions:

United States: Recent M&A Activity

✅ In October 2025, ESSA Pharma's shareholders approved its acquisition by XenoTherapeutics Inc., marking a strategic shift for ESSA Pharma, which was previously focused on prostate cancer drug development. The acquisition reflects the evolving landscape of oncology-focused M&A activity.

✅ In June 2025, Bristol Myers Squibb expanded its radiopharmaceutical portfolio by acquiring Philochem's prostate cancer drug, OncoACP3, for $350 million upfront, with potential milestones bringing the total deal value to over $1.3 billion. This acquisition aims to enhance BMS's capabilities in prostate cancer diagnostics.

✅ In June 2024, AstraZeneca completed the acquisition of Fusion Pharmaceuticals for approximately $2 billion in cash, gaining access to Fusion's next-generation radioconjugates, including FPI-2265, which is in mid-stage trials for metastatic castration-resistant prostate cancer.

Key Players:

=> Active Biotech AB, Diagnocure, Glaxosmithkline PLC, Northwest Biotherapeutics, Millennium Pharmaceuticals, Hologic, Spectrum Pharmaceuticals, Abbott Laboratories and Bayer Healthcare Pharmaceuticals.

Growth Forecast Projected:

The Global Castration Resistant Prostate Cancer Treatment Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Castration Resistant Prostate Cancer Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=castration-resistant-prostate-cancer-treatment-market

Key Segments:

➥ By Treatment: Chemotherapy, Hormonal Therapy, Targeted Therapy, Surgery, Others
➥ By End Users: Hospitals, Specialty Clinics, Diagnostic Laboratories, Others

Regional Analysis for Castration Resistant Prostate Cancer Treatment Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Castration Resistant Prostate Cancer Treatment producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Castration Resistant Prostate Cancer Treatment revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/castration-resistant-prostate-cancer-treatment-market?sb

FAQ

Q: What is the growth rate of the Castration Resistant Prostate Cancer Treatment Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 9% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.